NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.
Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug
NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill into late-stage trials.